



April 26, 2018  
JCR Pharmaceuticals Co., Ltd.

### **JCR Announces Construction of the Second Clinical Trial Material Manufacturing Center (tentative name)**

JCR Pharmaceuticals Co., Ltd., (TSE 4552: Chairman and President Shin Ashida, "JCR") announced the decision of the Board of Directors meeting held today to construct the Second Clinical Trial Material Manufacturing Center (tentative name) ("CTMC II") as follows.

1. Reason for construction of CTMC II

We expect an increasing number of drug candidate products and demand of their active pharmaceutical ingredient material for research and clinical development as we make good progress with our R&D programs. In light of such, we will construct a new manufacturing center for clinical trial material in the premises of our Murotani Plant (Nishi-ku, Kobe) as an additional facility to the existing ones in order to accelerate our R&D activities and ultimately to establish a comprehensive investigational drug supply system with a view for global expansion of JCR in the future. This CTMC II is aimed to be a multi-purpose site, serving not only for investigational drugs but also for preliminary research programs.

2. Overview of CTMC II

Location:	1-2-3 Murotani, Nishi-ku, Kobe
Start of construction:	March 2019
Completion of construction:	June 2020 (planned)
Scale:	2 stories above ground
Overall construction cost:	3 billion yen est.
Funding:	Self-financed including loans

3. View in the future

The expenditures estimated to construct CTMC II will mostly accrue in future years, and the effect on the consolidated performance of the Company is minor in this fiscal year (ending in March 2019).

We will continue our efforts to further strengthen our business activities and contribute to treatments for more patients as a specialty pharmaceutical company of therapeutic agents for rare diseases.

#### **[About JCR Pharmaceuticals]**

JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, "Contributing towards people's healthcare through pharmaceutical products" drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient community.

**[Cautionary Statement Regarding Forward-Looking Statements]**

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.*

*Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jcrpharm.co.jp](mailto:ir-info@jcrpharm.co.jp)

END

###